2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

9:00AM-10:30AM: Abstract Number: 2929

Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

9:00AM-10:30AM: Abstract Number: 2927

What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers?

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

9:00AM-10:30AM: Abstract Number: 2926

Which MRI Lesions in the Sacroiliac Joint Are Associated with the Diagnosis of Axial Spondyloarthritis after 2 Years Follow up in the Echography in Spondyloarthritis Cohort?

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

11:00AM-12:30PM: Abstract Number: 2950

10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2985

Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

11:00AM-12:30PM: Abstract Number: 2949

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2969

Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2975

Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

11:00AM-12:30PM: Abstract Number: 2992

Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

11:00AM-12:30PM: Abstract Number: 2997

Association between Payments By Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2980

Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2989

Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

11:00AM-12:30PM: Abstract Number: 2956

Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2988

Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

11:00AM-12:30PM: Abstract Number: 2973

Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.